Uses of Ezvasten

Ezvasten drug is often used in the treatment of patients with high cholesterol, coronary artery disease. So what does Ezvasten do and how does it work?

Ezvasten is a drug for the treatment of dyslipidemia, produced in the form of film-coated tablets. The main ingredients in each Ezvasten tablet include:
Calci Atorvastatin equivalent to Atorvastatin 20mg Ezetimibe 10mg Cholesterol in the blood has two origins: One is an exogenous source absorbed from the intestines and one endogenous source is synthesized by the body itself. fit. Ezvasten is a combination of two substances ezetimibe and atorvastatin, so it has cholesterol-lowering effects by both absorption and synthesis inhibition. Ezetimibe works to lower blood cholesterol by inhibiting the absorption of cholesterol in the small intestine. Atorvastatin is a synthetic lipid-lowering agent that inhibits the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase involved in cholesterol biosynthesis. Atorvastatin lowers total cholesterol, low-molecular-weight lipoprotein cholesterol (LDL-C), and also apolipoprotein B (apo B). Atorvastatin is also effective in lowering very low-molecular-weight lipoprotein (VLDL-C) and triglycerides (TG) cholesterol and increasing high-molecular-weight lipoprotein (HDL-C) cholesterol.
Ezvasten is indicated in the following cases:
Hypercholesterolemia Coronary artery disease: In patients with coronary artery disease associated with hypercholesterolemia, Ezvasten is indicated to reduce the risk of death from arterial disease. coronary artery disease, reducing the risk of non-fatal myocardial infarction, reducing the risk of myocardial revascularization, and at the same time slowing the process of coronary atherosclerosis, reducing the formation of new lesions. Ezvasten is contraindicated in the following cases:
People with hypersensitivity to any ingredient of the drug. Active liver disease or unexplained persistent elevations of transaminases. Patients with moderate to severe hepatic impairment. Pregnant and lactating women.

Ezvasten is used orally. You should follow a low cholesterol diet when you start using Ezvasten and continue to follow this diet for the entire time of treatment. Dosage of Ezvasten should be individualized based on plasma lipid levels.
Patients should start treatment with Ezvasten at the lowest effective dose, and then if necessary adjust the dose according to individual response by increasing the dose at intervals of not less than 4 weeks and Side effects of the drug must be monitored, especially adverse reactions to the muscle system.
The recommended dose of Ezvasten for each case is as follows:
The usual dose is 1 - 4 tablets / day, starting at a dose of 1 tablet / day. After 2 weeks, blood lipid levels should be rechecked. If necessary, adjust the dose of Ezvasten accordingly. Patients with Hepatic Impairment: No dose adjustment of Ezvasten is necessary in patients with mild hepatic impairment. Patients with renal impairment: No dose adjustment of Ezvasten is necessary in patients with mild or moderate renal impairment. However, for patients with severe renal impairment, Ezvasten can only be used if the patient can tolerate atorvastatin at a dose of 5 mg or higher. Ezvasten should be administered with caution to these patients and the patient should be carefully monitored. Elderly Patients: No dose adjustment of Ezvasten is necessary in elderly patients. Patients taking cyclosporin can only take Ezvasten if the patient can tolerate atorvastatin doses of 5 mg or more, but should not take more than 1/2 tablet per day. Patients taking amiodarone or verapamil should not take more than 1 tablet of Ezvasten per day.

When using Ezvasten, you may experience side effects of the drug. Common side effects of Ezvasten include:
Diarrhea, constipation, flatulence, abdominal pain and nausea. Headache, dizziness, blurred vision, insomnia, weakness. Muscle pain, joint pain. Liver function tests increased to more than 3 times the upper limit of normal, but the majority were asymptomatic and reversible upon discontinuation of the drug. Less common side effects of Ezvasten include:
Myopathy (combined muscle weakness and increased plasma creatine phosphokinase (CPK) levels). Skin board. Rhinitis , sinusitis, pharyngitis, cough. Rare side effects of Ezvasten include:
Myositis, rhabdomyolysis, leading to acute renal failure secondary to myoglobinuria. In addition, patients may also experience some other side effects when using Ezvasten:
Cognitive decline such as memory loss, confusion... Increased blood sugar. Increased HbAlc.

Inhibitors of CYP3A4 Enzymes: Taking Ezvasten with drugs that inhibit the CYP3A4 enzyme may increase blood levels of atorvastatin leading to an increased risk of myopathy and myopathy. Amiodarone: When Ezvasten is used with amiodarone, do not exceed 20 mg of atorvastatin/day because of the increased risk of rhabdomyolysis. For patients who need to take atorvastatin doses above 20mg/day to be effective, doctors may choose another lipid-lowering drug such as pravastatin. Coumarin Derivatives: Ezvasten slightly enhances the anticoagulant effect of coumarin. In patients receiving coumarin anticoagulants, prothrombin time should be checked before and during treatment with Ezvasten. Caution should be exercised when co-administering Ezvasten with niacin or other immunosuppressive agents. The risk of myopathy during treatment with Ezvasten is increased with concomitant use of cyclosporin, erythromycin, fibric acid derivatives, azole antifungals or niacin. Antacids: Concomitant administration of Ezvasten with antacid suspensions containing magnesium and aluminum hydroxide reduces plasma concentrations of atorvastatin by approximately 35%. However, the low-molecular-weight cholesterol-lowering effect of the drug did not change. Colestipol: When colestipol was administered with Ezvasten, the concentration of atorvastatin was reduced by approximately 25%. However, the lipid effect of the drug was increased with co-administration of atorvastatin and colestipol compared with the administration of either drug alone. Digoxin: When multiple doses of digoxin were administered concomitantly with 10 mg of atorvastatin, steady-state plasma digoxin concentrations were not affected. Digoxin concentrations increased by approximately 20% when used with 80 mg of atorvastatin daily. Active monitoring is recommended when administering Ezvasten to patients taking digoxin. Erythromycin / Clarithromycin: Concomitant use of Ezvasten and erythromycin (500 mg x 4 times/day) or clarithromycin (500 mg x 2 times/day) increases plasma concentrations of atorvastatin. Azithromycin: Co-administration of Ezvasten with doses of atorvastatin (10 mg once daily) and azithromycin (500 mg once daily) did not alter plasma concentrations of atorvastatin. Terfenadine: Co-administration of Ezvasten and terfenadine did not produce a clinically significant effect on the pharmacokinetics of terfenadine. Oral contraceptives: Co-administration of Ezvasten with an oral contraceptive containing norethindrone and ethinyl estradiol increases the AUC values ​​of norethindrone and ethinyl estradiol by approximately 30% and 20%. This should be considered when choosing an oral contraceptive for women using Ezvasten. Concomitant administration of Ezvasten and protease inhibitors that are cytochrome P450 3A4 inhibitors increases plasma concentrations of atorvastatin. Ezvasten is commonly used in the treatment of patients with high cholesterol and coronary artery disease. To ensure the effectiveness of treatment and avoid unwanted side effects, patients need to take the drug according to the prescription or consult a doctor, professional pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.